Skip to content
NBlaz – Lifestyle
Author:
OSR Health, Inc.
OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
August 19, 2026
OSR Health Sees Global Shareholder Momentum at Critical Inflection Point
August 19, 2026
OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development
August 11, 2026
OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program
August 7, 2026
Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform
August 3, 2026
OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment
July 31, 2026
OSR Health, A Message From the CEO
July 13, 2026
CORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
July 2, 2026
Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
July 2, 2026
OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares
June 25, 2026
1
2
Next Page
→